Hayden Trubitt, a shareholder in Stradling’s Corporate practice group, was quoted in an article published by Law.com, “Pharma Firm General Counsel on How Risk, Flexibility Delivered 'Home Run' With COVID-19 Drug.” Hayden represented Ligand Pharmaceuticals in its $35.5 million acquisition of CyDex Pharmaceuticals Inc. in 2011. CyDex holds the license for Captisol, a crucial ingredient in COVID-19 treatment drug remdesivir. He was also involved in Ligand’s licensing and supply agreement with Gilead. “It’s understood when you build a company with literally hundreds of shots on goal that most of them will be either zeros or not much. But a few will be home runs,” Trubitt said. “It’s an interesting business model and that’s how the company plays its game.”
Read the full article here.